Gilead Sciences Company Profile (NASDAQ:GILD)

About Gilead Sciences

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: GILD
  • CUSIP: 37555810
Key Metrics:
  • Previous Close: $69.85
  • 50 Day Moving Average: $71.76
  • 200 Day Moving Average: $75.36
  • 52-Week Range: $1,310,000,000.00 - $65.38
  • Trailing P/E Ratio: 7.03
  • Foreward P/E Ratio: 8.80
  • P/E Growth: -1.69
  • Market Cap: $91.50B
  • Outstanding Shares: 1,310,000,000
  • Beta: 1.11
  • Net Margins: 44.43%
  • Return on Equity: 92.36%
  • Return on Assets: 29.22%
  • Debt-to-Equity Ratio: 1.53%
  • Current Ratio: 4.17%
  • Quick Ratio: 4.00%
Additional Links:
Companies Related to Gilead Sciences:

Analyst Ratings

Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (?)
Ratings Breakdown: 10 Hold Ratings, 16 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $86.82 (24.30% upside)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)
DateFirmActionRatingPrice TargetDetails
2/16/2017Piper Jaffray CompaniesReiterated RatingOverweightView Rating Details
2/14/2017Stifel NicolausSet Price TargetBuy$87.00View Rating Details
2/14/2017J P Morgan Chase & CoSet Price TargetBuy$82.00View Rating Details
2/14/2017Berenberg BankSet Price TargetBuy$112.00 -> $78.00View Rating Details
2/14/2017Jefferies Group LLCReiterated RatingBuy$83.00View Rating Details
2/9/2017Barclays PLCReiterated RatingBuyView Rating Details
2/8/2017Leerink SwannSet Price TargetHold$91.00 -> $74.00View Rating Details
2/9/2017BMO Capital MarketsReiterated RatingHold$88.00 -> $75.00View Rating Details
2/8/2017RBC Capital MarketsLower Price Target$75.00View Rating Details
2/8/2017Needham & Company LLCReiterated RatingHoldView Rating Details
2/8/2017Robert W. BairdReiterated RatingOutperform$87.00View Rating Details
2/8/2017Citigroup Inc.DowngradeBuy -> Neutral$87.00 -> $76.00View Rating Details
2/8/2017Morgan StanleyLower Price TargetEqual Weight$85.00 -> $77.00View Rating Details
2/8/2017Wells Fargo & CompanyReiterated RatingMarket Perform$79.50 -> $65.50View Rating Details
2/8/2017Credit Suisse GroupLower Price TargetOutperform$93.00 -> $79.00View Rating Details
2/6/2017Cowen and CompanySet Price TargetBuy$100.00View Rating Details
1/28/2017William BlairReiterated RatingOutperformView Rating Details
1/13/2017Goldman Sachs Group, Inc. (The)Reiterated RatingHold$81.00View Rating Details
11/7/2016MizuhoInitiated CoverageBuy$88.00View Rating Details
11/6/2016Maxim GroupReiterated RatingHoldView Rating Details
11/2/2016Royal Bank Of CanadaLower Price TargetOutperform$95.00 -> $90.00View Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00View Rating Details
9/25/2016Bank of America CorpReiterated RatingNeutral$100.00View Rating Details
9/23/2016GabelliReiterated RatingBuyView Rating Details
7/29/2016ArgusDowngradeBuy -> Hold$88.00 -> $81.00View Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyView Rating Details
5/4/2016Oppenheimer Holdings, Inc.Reiterated RatingBuy$120.00 -> $116.00View Rating Details
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00View Rating Details
9/10/2015Jyske BankUpgradeStrong-Buy$125.00View Rating Details
7/29/2015Deutsche Bank AGBoost Price Target$125.00 -> $135.00View Rating Details
5/29/2015Sanford C. BernsteinReiterated RatingOutperform$125.00View Rating Details
2/27/2015NomuraSet Price TargetBuy$141.00View Rating Details
(Data available from 2/19/2015 forward)


Earnings History for Gilead Sciences (NASDAQ:GILD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2017Q416$2.61$2.70$7.16 billion$7.30 billionViewListenView Earnings Details
11/1/2016Q316$2.87$2.75$7.47 billion$7.40 billionViewListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details
4/30/2015Q115$2.32$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.19$2.43$6.68 million$7.31 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.73$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.85$1.48$3.80 billion$5.00 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Gilead Sciences (NASDAQ:GILD)
Current Year EPS Consensus Estimate: $8.57 EPS
Next Year EPS Consensus Estimate: $7.94 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$2.88$3.29$3.06
Q2 20162$3.03$3.25$3.14
Q3 20164$2.77$3.04$2.87
Q4 20163$1.14$2.62$2.06
Q1 20172$2.16$2.25$2.21
Q2 20172$2.05$2.14$2.10
Q3 20172$1.90$1.92$1.91
Q4 20172$1.78$1.82$1.80
(Data provided by Zacks Investment Research)


Current Dividend Information for Gilead Sciences (NASDAQ:GILD)
Annual Dividend:$1.88
Dividend Yield:2.69%
Payout Ratio:18.91% (Based on Trailing 12 Months of Earnings)
21.94% (Based on Current Year Consensus EPS Estimate)
23.68% (Based on Next Year Consensus EPS Estimate)

Dividend History for Gilead Sciences (NASDAQ:GILD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Gilead Sciences (NASDAQ:GILD)
Insider Ownership Percentage: 1.40%
Institutional Ownership Percentage: 74.19%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017John C MartinInsiderSell73,337$73.59$5,396,869.83View SEC Filing  
11/18/2016John W MadiganDirectorSell105,000$74.86$7,860,300.00View SEC Filing  
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.00View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.00View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.00View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.00View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.00View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.00View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.00View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.00View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Gilead Sciences (NASDAQ:GILD)
DateHeadline logoWhy Gilead Sciences Is a Buy (NASDAQ:GILD) - February 19 at 9:15 AM
News IconThe Technical Facts on Gilead Sciences Inc. (GILD) - The USA Commerce (NASDAQ:GILD) - February 18 at 12:26 PM logoGilead's HCV Guidance Wasn't Sandbagged - Seeking Alpha (NASDAQ:GILD) - February 18 at 12:26 PM logoWhy President Trump Should Buy Gilead Sciences (NASDAQ:GILD) - February 17 at 3:17 PM
News IconDigging Up the Facts on Gilead Sciences Inc. (GILD) - StockNewsJournal (NASDAQ:GILD) - February 17 at 8:53 AM
News IconGilead Sciences' (GILD) Market Perform Rating Reaffirmed at Wells Fargo & Company (NASDAQ:GILD) - February 16 at 10:21 PM logoGilead’s HIV Drug Reports Positive Data (GILD) (NASDAQ:GILD) - February 16 at 10:21 PM logoIs AbbVie The Next Gilead? (NASDAQ:GILD) - February 16 at 10:21 PM logoGilead Sciences (GILD) Shares Cross 3% Yield Mark (NASDAQ:GILD) - February 16 at 10:21 PM logoGilead Sciences (GILD) Value Trap (NASDAQ:GILD) - February 16 at 10:21 PM logoGilead’s HIV Drug Reports Positive Trial Data (NASDAQ:GILD) - February 16 at 10:21 PM logoUnder the Microscope: Gilead's Recent Dividend Increase (NASDAQ:GILD) - February 16 at 10:21 PM
News IconThe Technical Case for and Against Gilead Sciences Inc. (GILD) - The USA Commerce (NASDAQ:GILD) - February 16 at 5:21 PM logoWill Gilead Buy Bristol-Myers Squibb? - Seeking Alpha (NASDAQ:GILD) - February 16 at 5:21 PM logoGilead Sciences, Inc. (GILD): Bictegravir HIV Data Looks Good - Smarter Analyst (NASDAQ:GILD) - February 16 at 5:21 PM logoGilead Receives Approval in Canada for ODEFSEY™ for the Treatment of HIV-1 Infection (NASDAQ:GILD) - February 16 at 5:21 PM logoWhy It's a Colossal Mistake to Sell Gilead Sciences Stock Now (NASDAQ:GILD) - February 16 at 9:21 AM logo3:03 am Gilead Sciences reports Phase 3 studies for Genvoya demonstrating significantly higher rates of virologic suppression (NASDAQ:GILD) - February 15 at 4:58 AM logoGilead Sciences : Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults (NASDAQ:GILD) - February 14 at 11:39 PM logoGilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults (NASDAQ:GILD) - February 14 at 11:39 PM logoGilead Has 'Good News' But is it Enough? (NASDAQ:GILD) - February 14 at 6:38 PM logoNo Bottoming Signs Yet for Gilead (NASDAQ:GILD) - February 14 at 6:38 PM logoConsider Gilead Sciences (NASDAQ:GILD) - February 14 at 6:38 PM logoGilead Sciences: Not Out of the Woods Yet? (NASDAQ:GILD) - February 14 at 6:38 PM logoGilead (GILD) Announces Data on Combination Therapy for HIV (NASDAQ:GILD) - February 14 at 6:38 PM logoGilead HIV Drug Tops GSK Combo, But Rivalry 'Intense' With GSK Doublet (NASDAQ:GILD) - February 14 at 6:38 PM logoETFs with exposure to Gilead Sciences, Inc. : February 14, 2017 (NASDAQ:GILD) - February 14 at 6:38 PM logoWhy I Just Bought More Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - February 14 at 8:57 AM
News IconGilead Announces Findings from New Preclinical Study Evaluating Novel (NASDAQ:GILD) - February 14 at 4:26 AM logoGilead challenges GSK with strong HIV drug data (NASDAQ:GILD) - February 14 at 4:26 AM logoGilead Sciences : Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors (NASDAQ:GILD) - February 13 at 11:25 PM logoGilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV (NASDAQ:GILD) - February 13 at 11:25 PM logoGilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors (NASDAQ:GILD) - February 13 at 11:25 PM logo6:47 pm Gilead Sciences announces findings from new preclinical study evaluating novel class of HIV capsid inhibitors that support continued investigation (NASDAQ:GILD) - February 13 at 11:25 PM logoGilead and 'Good News' Make A Rare, Joint Appearance at HIV Conference (NASDAQ:GILD) - February 13 at 11:25 PM
News IconAnalytical Preview of Gilead Sciences Inc. (NASDAQ:GILD) (NASDAQ:GILD) - February 13 at 6:22 PM logoGilead Sciences Activist Chatter Spurs Short-Term Call Buying (NASDAQ:GILD) - February 13 at 6:22 PM logoIs Gilead Sciences Getting Ready for a Massive Acquisition? (NASDAQ:GILD) - February 13 at 6:21 PM logoCan Gilead Swivel To HIV Amid Floundering Hep C Sales, GSK Rivalry? (NASDAQ:GILD) - February 13 at 6:21 PM
News IconGilead Sciences, Inc. (NASDAQ:GILD) Continues The Falling Streak For Q4 2016; Reports $3.1 Billion Net Income (NASDAQ:GILD) - February 13 at 11:47 AM logoAllergan Shares Rise on $2.5B Deal for Body-Sculptor Zeltiq (NASDAQ:GILD) - February 13 at 11:47 AM
News IconWhy Gilead Sciences, Inc. Can Bounce Back: A Delicious 3% Dividend Yield (NASDAQ:GILD) - February 12 at 3:32 AM logoWhat Analysts Are Prescribing Gilead After Earnings (NASDAQ:GILD) - February 11 at 5:29 PM logoGilead: Buy When Others Are Selling (NASDAQ:GILD) - February 10 at 6:04 PM logoThese 5 Stocks Are Showing Red Flags in February (NASDAQ:GILD) - February 10 at 6:04 PM logoWhy Gilead's Disastrous Forecast is Good News for Biotech (NASDAQ:GILD) - February 10 at 6:04 PM logoGilead Bombs - Analysis - Seeking Alpha (NASDAQ:GILD) - February 10 at 4:17 AM logoGilead Sciences, Inc. (GILD) Stock Tumbles on Dismal Guidance - (NASDAQ:GILD) - February 10 at 4:17 AM logoGilead Could Go Lower - Seeking Alpha (NASDAQ:GILD) - February 10 at 4:17 AM logoGilead Sciences, Inc. Is A Weak Stock That Keeps Getting Weaker (NASDAQ:GILD) - February 9 at 6:11 PM


What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Tuesday, February 7th. Shareholders of record on Thursday, March 16th will be paid a dividend of $0.52 per share on Thursday, March 30th. This represents a $2.08 annualized dividend and a yield of 2.98%. The ex-dividend date is Tuesday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.47.

Where is Gilead Sciences' stock going? Where will Gilead Sciences' stock price be in 2017?

27 brokers have issued 1 year price targets for Gilead Sciences' stock. Their forecasts range from $65.50 to $116.00. On average, they expect Gilead Sciences' stock price to reach $86.82 in the next twelve months.

When will Gilead Sciences announce their earnings?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.

What are analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

  • Jefferies Group LLC analysts commented, "Though expectations were relatively high going into the data, "sneak peek" at bic vs. dolu HTH ph.III HIV data at evening CROI press conference show GILD's integrase trending towards better efficacy vs. dolu-- explaining co's recent enthusiasm. Small study, but much needed good news for GILD and recall bictegravir will help maintain LT HIV franchise post-2025. Expect upside on increasing comfort on HIV franchise longevity given increasing dependence on HIV." (2/14/2017)
  • According to Zacks Investment Research, "Although Gilead’s fourth quarter results beat on both earnings and sales, the guidance for 2017 was disappointing. The HCV franchise continues to be under competitive and pricing pressure due to which the sales of Harvoni and Sovaldi have declined. Total HCV treatment starts in the U.S. were an estimated 231,000 in 2016, approximately 25,000 less than 2015. The company expects a further decline in patients starts in 2017. In addition, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. Shares of Gilead have underperformed the biotech industry in the past one year. On a positive note, Epclusa’s uptake has been encouraging while the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales." (2/13/2017)

  • Needham & Company LLC analysts commented, "Gilead reported 4Q16 financial results yesterday. Total 4Q16 revenue of $7.32B exceeded our $6.86B and consensus $7.14B estimates, driven by strong Epclusa launch in HCV ($1.05B WW). HCV sales overall, however, continue to fall and mgmt issued 2017 sales guidance below expectations. We remain cautious given revenue trajectory and maintain HOLD." (2/8/2017)
  • Cowen and Company analysts commented, "Effective Jan. 1, the U.S. price of Atripla has been increased by 2.3%." (1/6/2017)

  • RBC Capital Markets analysts commented, "We should see BLA acceptance on CHS-1701 on or before October 9; we should see an AdComm in April 2017 and approval soon thereafter; launch timing depends on need for 180- day waiting period. While Sandoz has not disclosed the reason for its CRL, we believe the company could be set back 2-3 years." (10/3/2016)

Who owns Gilead Sciences stock?

Gilead Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.59%), FMR LLC (2.97%), Franklin Resources Inc. (1.09%), Temasek Holdings Private Ltd (1.06%), Renaissance Technologies LLC (0.40%) and AQR Capital Management LLC (0.32%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter, Richard James Whitley and Robin L Washington.

Who sold Gilead Sciences stock? Who is selling Gilead Sciences stock?

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Edgewood Management LLC, Levin Capital Strategies L.P., Investec Asset Management LTD, Orbimed Advisors LLC, Fred Alger Management Inc., Janus Capital Management LLC and Thornburg Investment Management Inc.. Company insiders that have sold Gilead Sciences stock in the last year include Gayle E Wilson, Gregg H Alton, John C Martin, John F Milligan, John W Madigan, Kevin E Lofton and Paul Rutherford Carter.

Who bought Gilead Sciences stock? Who is buying Gilead Sciences stock?

Gilead Sciences' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, State Street Corp, Asset Management One Co. Ltd., FIL Ltd, Russell Investments Group Ltd., Elkfork Partners LLC, Prudential PLC and ANTIPODES PARTNERS Ltd.

How do I buy Gilead Sciences stock?

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Gilead Sciences stock cost?

One share of Gilead Sciences stock can currently be purchased for approximately $69.85.

Gilead Sciences (NASDAQ:GILD) Chart for Sunday, February, 19, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Earnings History Chart

Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)

Dividend History Chart

Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Last Updated on 2/19/2017 by Staff